血浆 EGFR 基因检测在肺腺癌中的应用及与预后相关性的初步探讨
摘要
关键词
全文:
PDF参考
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012 [J].International Journal of Cancer, 2015,136 (5): E359-E386.
苏飞,郑可,付祎云,等.不同治疗对肺癌患者血液循环游离 DNA检测EGFR 基因突变的影响及预后分析[J].中国肺癌杂志,2018,21(5):389-396.
Su KY, Chen HY, Li KC, et al. Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients with Non-small-cell Lung Cancer[J].Clin Oncol,2012,30(4):433-440.
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors[J].Sci Trans Med,2011,3(75):75-126.
Douillard J Y, Ostoros G, Cobo M, et al. Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status [J].Journal of Thoracic Oncology,2014,9(9):1345-1353.
DOI: https://doi.org/10.36012/pmr.v2i1.1323
Refbacks
- 当前没有refback。